Clinical Trial on Remote Ischemic Preconditioning and Cerebral Small Vessel Disease

Capital Medical University30 enrolled

Overview

The hypothesis of this study is that remote ischemic preconditioning (RIPC) might have a beneficial effect on outcomes of cerebral small vessel disease (CSV).

CSV constitutes an important type of ischemic stroke due to a generalized hypo-perfusion of brain. Few treatment methods are available except some beneficial effect shown with nimodipine. The potential treatment effect of RIPC on protection of brain from cerebral small vessel disease has not been investigated. The investigators designed this randomized, double-blind, controlled clinical trial to examine (1) whether RIPC has a beneficial effect on brain lesions of CSV, and (2) whether RIPC can protect patients of CSV from cognitive deterioration. There are 2 arms in this trial: One arm is RIPC treatment, the other one is sham RIPC treatment. Brain lesions will be quantified by volumetric MRI, and Xe-CT will be used to evaluate cerebral blood perfusion. Cognitive function will be evaluated by mini-mental state examination (MMSE) and the Montreal Cognitive Assessment (MoCA).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Cerebral Small Vessel Disease

Interventions

remote ischemic preconditioningPROCEDURE

RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.

sham remote ischemic preconditioningPROCEDURE

Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects aged 40-80 years; 2. Ischemic cerebrovascular event onset, if any, must be within 6 months; 3. TCD and carotid ultrasound exclude vascular narrow that can cause hemodynamic changes (usually \>50% narrow lumen); 4. MRI confirmed the presence of lacunar infarction and / or generalized white matter lesions; 5. Written consent was obtained from the subject. Exclusion Criteria: 1. History of intracranial hemorrhage; 2. Significant bleeding from other parts of the body; 3. History of atrial fibrillation; 4. History of myocardial infarction within six months; 5. Moyamoya disease or vasculitis; 6. Hereditary small vessel disorders, such as CADASIL, FABRY, and mitochondrial encephalo-myopathy; 7. Significant bleeding-coagulation dysfunction; 8. Abnormal blood pressure, glucose and/or lipids after restrict treatment regimen; 9. Severe liver/kidney disease, cancer or critical illness of internal medicine and surgery.

Locations (1)

Xuan Wu Hospital

Beijing, China

Outcomes

Primary Outcomes

changes in brain lesions

Volumetric MRI will be used for calculating changes in the number of lacunar infarctions and the total volume of white matter lesions

Time frame: 0-24 months

Secondary Outcomes

Changes in the cognitive function

Cognitive function will be evaluated by mini-mental state examination (MMSE) and the Montreal Cognitive Assessment (MoCA).

Time frame: 0-24 months

Changes in the cerebral blood perfusion

Cerebral blood perfusion will be evaluated by Xe-CT.

Time frame: 0-24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.